Business
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Nurix CSO Gwenn M. Hansen, Ph.D., invited as a featured presenter in two separate sessions focused on next-gen degraders and delivering degraders to the site
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"Nurix CSO Gwenn M. Hansen, Ph.D., invited as a featured presenter in two separate sessions focused on next-gen degraders and delivering degraders to the site of action\nSAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, is invited as a featured speaker in two sessions at the American Association for Cancer Research (AACR) 2024 Annual Meeting, which will be held from April 5-10, 2024, in San Diego, CA. Dr. Hansen’s presentation “NX-5948, a brain-penetrant BTK degrader with clinical activity in B-cell malignancies including CNS lymphoma” will be featured in the Major Symposium session: Molecular Glues, PROTACs, and Next-Gen Degraders: Discovery and Early Preclinical Advances that will be held from 10:15 -11:45 a.m. PT on Tuesday, April 9, 2024. Dr. Hansen is also a featured presenter in the Educational session: Chemistry to the Clinic Part 1 of 3: Targeted Protein Degraders: Delivering Degraders to the Site of Action that will be held from 4:45 - 6:15 p.m. PT on Friday, April 5, 2024. About NX-5948 NX-5948 is an investigational, orally bioavailable, small molecule degrader of Bruton’s tyrosine kinase (BTK). NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Nurix has previously reported that NX-5948 is highly potent against a range of tumor cell lines that are resistant to current BTK inhibitor therapies, an important consideration in heavily pretreated CLL/SLL patient populations. Additional information on the ongoing clinical trial can be accessed at clinicaltrials.gov (NCT05131022). About Nurix Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and ad...